SB3434, titled the Health Coverage Across State Lines Act, would amend the Public Health Service Act to allow individual health insurance coverage to be sold across state lines under a “primary State” model. Under the bill, an insurer would choose one state whose laws would govern the policy, and that state’s rules would generally apply to the coverage even when sold to residents of other states. The bill is framed as a way to increase competition, reduce costs, and make individual market coverage more accessible by letting insurers operate under a single regulatory regime rather than complying with every state’s individual insurance mandates.
The bill sets out detailed definitions and conditions for cross-state sales, including requirements that the insurer be licensed in the primary state, that the policy already be offered in that primary state before being sold elsewhere, and that consumers receive a prominent disclosure explaining that the policy may be less expensive because it is not subject to all laws of the consumer’s home state. It also preserves certain secondary-state powers, such as collecting taxes, requiring registration for service of process, enforcing fraud and abuse laws, enforcing unfair claims settlement practices, and requiring independent external review procedures. The bill further prohibits reclassifying insured individuals or raising premiums at renewal based on health-status factors or prior claims experience, while allowing some premium changes tied to class-wide claims experience, wellness programs, or misrepresentation.
If enacted, the bill would significantly alter the balance between state insurance regulation and interstate insurance sales by preempting many secondary-state insurance laws for qualifying individual market policies. It would amend Title XXVII of the Public Health Service Act to create a new federal framework for cooperative governing of individual health insurance coverage, while leaving certain state enforcement powers intact. The bill also requires the Government Accountability Office to conduct an ongoing study and issue annual reports for five years on effects such as uninsured rates, affordability, access for people with pre-existing conditions, benefit reductions, and fraud or abuse.
The general sentiment reflected in the bill text is strongly pro-market and pro-deregulation, emphasizing affordability, competition, and interstate commerce. There is no recorded committee debate or vote history in the provided materials, so no formal legislative support or opposition can be measured from hearings or roll calls. The findings section, however, makes clear that the bill’s sponsors view current state-by-state regulation and Affordable Care Act requirements as barriers to lower-cost coverage.
The main point of contention is likely to be the extent to which the bill would weaken home-state consumer protections and benefit mandates. Critics would likely focus on the bill’s preemption of secondary-state insurance laws, the possibility of policies being sold with fewer mandated benefits, and the risk that consumers could purchase cheaper but less comprehensive coverage. Supporters would likely argue that the bill preserves core anti-fraud, claims, and review protections while expanding consumer choice and lowering premiums through interstate competition.
The bill would add a new Part F to Title XXVII of the Public Health Service Act establishing a federal framework for interstate sale of individual health insurance coverage. It would preempt many insurance laws of a consumer’s home state for policies sold under the bill’s conditions, while preserving limited secondary-state authority over taxes, service of process, fraud, unfair claims practices, insolvency-related actions, and external review. It would also require GAO oversight through ongoing study and annual reports, and it would apply only to policies offered, issued, or sold one year after enactment.
The bill’s tone is generally supportive of expanded interstate insurance competition and reduced regulatory burden. The findings argue that state-law variation and ACA-related mandates raise costs and restrict access, suggesting the bill is intended to lower premiums and broaden availability. No committee transcripts or votes were provided, so there is no recorded legislative sentiment beyond the bill’s own pro-expansion framing.
The central controversy is federal preemption of state insurance regulation. Opponents would likely object that the bill allows insurers to sell into other states under the laws of a single primary state, potentially bypassing home-state benefit mandates, consumer protections, and rate restrictions. Supporters would likely counter that the bill preserves key safeguards such as fraud enforcement, claims settlement rules, and independent review, and that it still bars health-status-based reclassification and renewal premium increases. The tension is therefore between consumer protection through state regulation and affordability through interstate market access.